Metris Therapeutics Ltd.

This article was originally published in Start Up

01 Oct 2000
Analysis

Melanie Senior melanieannsenior@gmail.com

Executive Summary

Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

Topics

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Platform Technologies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC090304

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC090304

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Metris Therapeutics Ltd.

Analysis

Executive Summary

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert